1.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: OXC4T4-302, NCT00507429
|
|
2.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 14295, EudraCT: 2009-012007-25, NCT00984282
|
|
3.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 5 to 18
Sponsor: NCI
Protocol IDs: NCI-07-C-0189, 07-C-0189, NCT00514046
|
|
4.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: MDA-2004-0059, 6132, NCI-6132, NCT00104871
|
|
5.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: CASE-5304, CASE 5304, 7037, NCI-7037, NCT00126568
|
|
6.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: UCCRC-14696A, 14696A, 7735, NCI-7735, NCT00381641
|
|
7.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: OSU-06054, 7609, IRB 2006C0050, NCI-7609, NCT00390325
|
|
8.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A4061027, NCT00389441
|
|
9.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: Valproic Acid, NCT00525135
|
|
10.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Not specified
Sponsor: NCI
Protocol IDs: UPCC-03305, UPCC#03305, UPCC-802861, NCT00601783
|
|
11.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: MAYO-MC057H, MC057H, 7627, NCT00625846
|
|
12.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 802861, UPCC 03305, NCT00654238
|
|
13.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: MSKCC-08066, 08-066, 7508, NCT00729157
|
|
14.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: E7080-G000-201, NCT00784303
|
|
15.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 090138, 09-C-0138, NCT00923481
|
|
16.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 09-049, NCT00936858
|
|
17.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-03-C-0030, NCI-5483, 5483, NCT00052767
|
|
18.
|
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-07-C-0047, NCI-P6880, NCT00436735
|
|
19.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 04-116, NCT00673010
|
|
20.
|
Phase: No phase specified
Type: Diagnostic, Treatment
Status: Active
Age: 18 to 100
Sponsor: NCI
Protocol IDs: JHOC-J0628, NCT00416949
|
|
21.
|
Phase: No phase specified
Type: Diagnostic, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: GE-135-003, NCT00565721
|
|
22.
|
Phase: No phase specified
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: COMIRB# 07-0727, NCT00718770
|
|
23.
|
Phase: No phase specified
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 09-048, NCT00970359
|
